SL Science Holding Limited (SLBT) Key Metrics
SLBT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $858.0M
- Enterprise value
- $907.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 262.4
- Price / book
- 397.8
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
SLBT key metrics, 2023–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSLBT returns How much profit the business earns on the capital it uses.
SLBT per-share figures Results divided by the shares outstanding at year-end.
SLBT financial health Debt, liquidity and how easily interest is covered.
SLBT efficiency & capital use Working capital cycle and where the cash goes.
SLBT returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SLBT debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SLBT price vs earnings per share
SLBT key metrics
2023–2025| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Valuation | |||
| Market capitalization | $5.91B | — | — |
| Enterprise value | $5.91B | — | — |
| Earnings yield | −0.1% | — | — |
| Free cash flow yield | −0.0% | — | — |
| Share price at fiscal year-end | $10.54 | — | — |
| Per share | |||
| Revenue per share | $0.00 | $0.01 | $0.00 |
| Earnings per share | −$0.01 | −$0.00 | $0.00 |
| Operating cash flow per share | −$0.00 | $0.00 | −$0.00 |
| Free cash flow per share | −$0.00 | $0.00 | −$0.00 |
| Cash per share | $0.00 | $0.01 | $0.00 |
| Book value per share | $0.00 | $0.01 | $0.01 |
| Tangible book value per share | $0.00 | $0.01 | $0.01 |
| Capex per share | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.00 | — | $0.00 |
| Shares outstanding | 560.8M | 560.8M | 560.8M |
| Change in shares outstanding | 0.0% | 0.0% | — |
| Returns & profitability | |||
| Return on equity (ROE) | −95.4% | −25.6% | 11.2% |
| Return on invested capital (ROIC) | −184.5% | −32.1% | 1.9% |
| Return on assets (ROA) | −87.3% | −23.4% | 9.4% |
| Return on tangible assets | −135.6% | −20.1% | 9.4% |
| Free cash flow margin | −101.5% | 8.1% | −300.0% |
| Income quality (OCF / net income) | — | — | −6.15 |
| Financial health | |||
| Total debt | $213,405 | — | $550,064 |
| Cash & short-term investments | $1.3M | $3.7M | $276,854 |
| Net debt | −$1.0M | −$3.7M | $273,210 |
| Debt / equity | 0.09 | — | 0.15 |
| Debt / assets | 0.08 | — | 0.13 |
| Net debt / EBITDA | — | — | 2.04 |
| Current ratio | 3.05 | 84.61 | 19.09 |
| Quick ratio | 3.05 | 64.96 | 11.01 |
| Working capital | $958,290 | $5.8M | $3.3M |
| Invested capital | $1.2M | $2.0M | $3.8M |
| Tangible asset value | $2.3M | $5.7M | $3.6M |
| Net current asset value | $893,548 | $5.7M | $2.8M |
| Graham number | — | — | $0.01 |
| Graham net-net per share | $0.00 | $0.01 | $0.00 |
| Capital allocation | |||
| Capex / revenue | 14.5% | 0.2% | 20.8% |
| Capex / operating cash flow | — | 2.8% | — |
| Capex / depreciation | 3.41 | 0.17 | 4.92 |
| R&D / revenue | 94.2% | 60.1% | — |
| SG&A / revenue | 115.8% | 33.0% | 72.9% |
| Efficiency | |||
| Days sales outstanding | 32.8 | 20.8 | 49.1 |
| Days of inventory on hand | — | 362.0 | 3,828.0 |
| Receivables turnover | 11.13 | 17.54 | 7.43 |
| Inventory turnover | — | 1.01 | 0.10 |
| Asset turnover | 0.50 | 0.66 | 0.21 |
| Average receivables | $197,490 | $191,781 | $118,280 |
| Average inventory | $679,886 | $1.4M | $1.5M |
| Intangibles / total assets | 0.0% | 0.0% | 0.2% |
Computed from SLBT's annual financial statements (latest annual report filed December 31, 2025) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SLBT valuation and financial ratios
SL Science earned a return on equity of −95.4% and a return on invested capital of −184.5% in fiscal 2025. It ended the year with $0.2 million of debt and $1.3 million in cash and short-term investments, a net cash position of $1.0 million.
See the SLBT income statement, the SLBT chart for price history, or the SLBT stock overview for the latest quote and news.
SLBT key metrics FAQ
What is SL Science's return on equity?
SL Science's return on equity (ROE) was −95.4% in fiscal 2025: net income of -$3.8 million on average shareholders' equity of $4.0 million.
What is SL Science's ROIC?
SL Science's return on invested capital was −184.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does SL Science have?
SL Science had total debt of $0.2 million at the end of fiscal 2025, a debt-to-equity ratio of 0.09 and more cash than debt.
What is SL Science's free cash flow yield?
SL Science generated -$2.2 million of free cash flow in fiscal 2025, a free cash flow yield of −0.0% on its market value at year-end ($5.9 billion).
What is SL Science's current ratio?
SL Science's current ratio was 3.05 at the end of fiscal 2025: current assets were 3.05 times current liabilities.